




RealRate

PHARMACEUTICAL 2024

Cumberland Pharmaceuticals INC
Rank 152 of 309



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cumberland Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cumberland Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Cumberland Pharmaceuticals INC is the variable Assets, Current, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 219%, being 5.4% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	35,714
Cost of Goods Sold	6,067
Intangible Assets	23,522
Liabilities, Current	27,982
Liabilities, Non-Current	11,750
Other Assets	22,172
Other Compr. Net Income	0
Other Expenses	27,268
Other Liabilities	12,784
Other Net Income	1,109
Other Revenues	42,381
Property and Equipment	368
Research and Development	5,834
Selling, General and Administrative Expense	10,652

Output Variable	Value in 1000 USD
Assets	81,776
Liabilities	52,516
Expenses	49,821
Revenues	42,381
Stockholders Equity	29,260
Net Income	-6,331
Comprehensive Net Income	-6,331
BaseVar	113,802
ECR before Limited Liability	86%
Economic Capital Ratio	219%